Regenxbio (RGNX) Misses Q3 EPS by 22c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
REGENXBIO Reports Third Quarter 2019 Financial and Operating Results and Recent Operational Highlights
November 5, 2019 4:05 PM ESTROCKVILLE, Md., Nov. 5, 2019 /PRNewswire/ --
Initiation of RGX-314 Phase IIb trial for wet AMD and IND filing for Phase II trial in diabetic retinopathy now expected in Q1 2020 as a result of partial clinical hold following FDA notification related to certain commercial, third-party surgical devices; matter is not related to RGX-314 gene therapy candidate Positive interim update from RGX-314 Phase I/IIa trial for wet AMD presented in October at AAO Well-tolerated at all doses Anti-VEGF treatment burden was decreased by over 80% in Cohort 5,... More